New York, United States:
Johnson & Johnson stays “very confident” in its Covid-19 vaccine and longing for a fast decision from regulators over its standing, a high government stated Tuesday.
“We remain very confident and very hopeful that the benefit-risk profile will play out,” J&J Chief Financial Officer Joseph Wolk informed CNBC.
The feedback got here forward of a call anticipated later Tuesday from Europe’s drug regulator on the protection of the single-shot innoculation.
US pandemic advisor Anthony Fauci stated the United States is prone to announce its determination by Friday.
Health authorities within the United States on April 14 beneficial a pause on the vaccine following six cases of extreme blood clots out of practically seven million Americans who obtained the vaccine.
The firm hopes “very shortly … perhaps as early as the end of this week, to have some resolution with how we are going to proceed,” Wolk stated.
Asked if the US determination to droop this system hindered public confidence in vaccines, Wolk stated “I would hope that at the end of the week, the population in general will feel more confident in taking the vaccine.”
The feedback got here as J&J launched first-quarter outcomes.
An earnings press launch didn’t elaborate on vaccine approval points, however stated the vaccine generated $100 million in revenues within the United States throughout the interval. J&J is promoting the vaccine at value.
J&J has additionally encountered manufacturing issues at a Baltimore, Maryland manufacturing unit managed by Emergent BioSolutions.
The Food and Drug Administration has suspended manufacturing within the plant pending a evaluate of the ability.
Wolk stated J&J expects to be “in a position to meet our contract commitments, not just here in the US but across the globe” following the FDA evaluate.